Hydroxychloroquine Sulfate Ipca Laboratories Uk

Hydroxychloroquine Sulfate, the active ingredient in Hydroxychloroquine Sulfate Ipca Laboratories Uk, is an antimalarial and immunomodulator presented as an oral tablet for systemic use. Classified under ATC code P01BA02, it is used for malaria prophylaxis and treatment, and for chronic autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus in adults.

GNH USA supplies Hydroxychloroquine Sulfate Ipca Laboratories Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Hydroxychloroquine Sulfate is employed in the management of parasitic infections and autoimmune disorders.

- Malaria: Provides prophylaxis and treatment of acute Plasmodium infections. - Rheumatoid arthritis: Reduces disease activity and joint inflammation in adult patients. - Systemic lupus erythematosus: Controls disease flares and organ involvement.

Hydroxychloroquine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or upset stomach. - Headache. - Abdominal pain or diarrhea. - Skin rash or mild itching. - Transient visual disturbances such as blurred vision. - Mild dizziness.

Serious or Rare Side Effects: - Retinopathy leading to permanent vision loss. - Cardiomyopathy or QT‑interval prolongation. - Severe hypoglycemia, especially in diabetic patients. - Hematologic abnormalities (e.g., agranulocytosis, thrombocytopenia). - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychiatric effects including mood changes or psychosis.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Pregnancy: Category B; use only when clearly needed after risk‑benefit evaluation. - Renal impairment: Adjust dose and monitor renal function regularly. - Retinal screening: Baseline ophthalmologic exam and annual follow‑up are recommended. - Cardiac monitoring: Evaluate QT interval in patients with cardiac risk factors. - Drug interactions: Review concomitant medications for major interaction potential. - Store at ambient temperature below 25°C: keep in original container, protect from moisture.

Hydroxychloroquine can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Azithromycin: additive risk of QT prolongation. - Quinine: combined cardiotoxic potential. - Amiodarone: heightened QT‑interval prolongation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase hydroxychloroquine plasma levels. - Retinal toxic agents (e.g., tamoxifen): may exacerbate ocular toxicity.

Moderate Interactions (Monitor Closely): - Antidiabetic agents (insulin, sulfonylureas): may potentiate hypoglycemia. - NSAIDs: increased risk of renal impairment. - Anticoagulants (warfarin): possible alteration of INR. - CYP3A4 inducers (carbamazepine, phenytoin): may reduce hydroxychloroquine exposure. - Live vaccines: potential reduction in vaccine efficacy.